이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Everest Medicines 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Rogers Luo

최고 경영자

CN¥30.7m

총 보상

CEO 급여 비율	23.5%
CEO 임기	2yrs
CEO 소유권	0.3%
경영진 평균 재임 기간	2.3yrs
이사회 평균 재임 기간	3yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Rogers Luo 의 보수는 Everest Medicines 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-CN¥1b
Mar 31 2024	n/a	n/a	-CN¥949m
Dec 31 2023	CN¥31m	CN¥7m	-CN¥844m
Sep 30 2023	n/a	n/a	-CN¥424m
Jun 30 2023	n/a	n/a	-CN¥3m
Mar 31 2023	n/a	n/a	-CN¥125m
Dec 31 2022	CN¥8m	CN¥2m	-CN¥247m

보상 대 시장: Rogers 의 총 보상 ($USD 4.31M )은 German 시장( $USD 1.46M ).

보상과 수익: 회사가 수익성이 없는 동안 Rogers 의 보상이 증가했습니다.

CEO

Rogers Luo (54 yo)

2yrs

테뉴어

CN¥30,722,000

보상

Mr. Yongqing Luo, also known as Rogers, is CEO & Executive Director of Everest Medicines Limited from September 19, 2022. He was President and General Manager of Greater China at Brii Biosciences Limited a...

리더십 팀

이름	위치	테뉴어	보상	소유권
Fu Wei	Executive Chairman	7.2yrs	데이터 없음	0.60% CN¥ 6.0m
Yongqing Luo	CEO & Executive Director	2yrs	CN¥30.72m	0.31% CN¥ 3.1m
Ian Ying Woo	CFO, President & Executive Director	6.3yrs	CN¥18.46m	0.063% CN¥ 635.5k
Jason M. Brown	Chief Business Officer	5.1yrs	데이터 없음	데이터 없음
Wei Yang	Chief Scientific Officer	3.4yrs	데이터 없음	데이터 없음
Steve Xu	Chief Legal & Compliance Officer	less than a year	데이터 없음	데이터 없음
Rico Liang	Chief Product Officer	less than a year	데이터 없음	데이터 없음
Sandra Zeng	Chief Medical Officer	less than a year	데이터 없음	데이터 없음
Yee Wa Lau	Joint Company Secretary	no data	데이터 없음	데이터 없음
Leah Liu	Joint Company Secretary & VP of Corporate Affairs	2.5yrs	데이터 없음	데이터 없음

2.3yrs

평균 재임 기간

51yo

평균 연령

경험이 풍부한 관리: 6HN 의 관리팀은 경험 ( 2.2 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Fu Wei	Executive Chairman	7.2yrs	데이터 없음	0.60% CN¥ 6.0m
Yongqing Luo	CEO & Executive Director	2yrs	CN¥30.72m	0.31% CN¥ 3.1m
Ian Ying Woo	CFO, President & Executive Director	5.8yrs	CN¥18.46m	0.063% CN¥ 635.5k
Yifan Li	Independent Non-Executive Director	4yrs	CN¥401.00k	데이터 없음
Ki Chul Cho	Non-Executive Director	less than a year	데이터 없음	데이터 없음
Shidong Jiang	Independent Non-Executive Director	4yrs	CN¥401.00k	데이터 없음
Hoi Yam Chui	Independent Non-Executive Director	1.7yrs	CN¥352.00k	데이터 없음
Honggang Feng	Non-Executive Director	less than a year	데이터 없음	데이터 없음

3.0yrs

평균 재임 기간

54.5yo

평균 연령

경험이 풍부한 이사회: 6HN 의 이사회는 경험(평균 재직 기간 3 년)으로 간주됩니다.

Everest Medicines 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Everest Medicines Limited, Annual General Meeting, Jun 28, 2024

Everest Medicines Strengthens Management Team with Appointments of Chief Medical Officer and Chief Product Officer

Everest Medicines Limited Announces Board Changes

Everest Medicines Limited Announces Directorate Changes

Everest Medicines Appoints Mike Berry as Chief Technology Officer

Everest Medicines Limited, Annual General Meeting, Jun 29, 2023

Recent updates

First half 2024 earnings released

No longer forecast to breakeven

New minor risk - Profitability

Everest Medicines Limited to Report First Half, 2024 Results on Aug 27, 2024

Everest Medicines Announces First Chinese Patient Dosed in Global Phase 2b PALIZADE Trial of Zetomipzomib in Lupus Nephritis

Now 21% undervalued after recent price drop

Everest Medicines Announces Official Acceptance Granted on NEFECON® Supplementary Application by China National Medical Products Administration

Everest Medicines Announces Positive Topline Results from Maintenance Period of Etrasimod Phase 3 Clinical Trial Conducted in Asia for the Treatment of Moderately-to-Severely Active Ulcerative Colitis

Everest Medicines Limited, Annual General Meeting, Jun 28, 2024

Everest Medicines Announces Commercial Launch and First Prescription for NEFECON in Mainland China

Now 22% overvalued after recent price rise

Everest Medicines Announces New Drug Application Approval of Velsipity® for Adults with Moderately to Severely Active Ulcerative Colitis in Macau

Everest Medicines Announces Hong Kong Department of Health Approval of Nefecon® for the Treatment for Primary IgA Nephropathy in Adult Patients

Full year 2023 earnings released

Forecast to breakeven in 2026

Everest Medicines Strengthens Management Team with Appointments of Chief Medical Officer and Chief Product Officer

Now 23% overvalued after recent price rise

Everest Medicines Limited to Report Fiscal Year 2023 Results on Mar 27, 2024

Everest Medicines Limited Announces Board Changes

Now 22% undervalued after recent price drop

Everest Medicines Limited Provides Earning Guidance for the Year Ended 31 December 2023

Everest Medicines Limited Announces Directorate Changes

Everest Medicines Announces New Drug Application Acceptance of Nefecon® in Taiwan for the Treatment of Primary IgA Nephropathy in Adult Patients

Everest Medicines Reaffirms Revenue Guidance for the Year 2023 and 2024

Calliditas’ Partner Everest Medicines Announces China NMPA’s Approval of Nefecon® for the Treatment of Primary IgA Nephropathy

National Medical Products Administration Approves the New Drug Application for Nefecon for the Treatment of Primary Immunoglobulin A Nephropathy in Adults At Risk of Disease Progress in China

Everest Medicines Announces New Drug Application Approval by the Pharmaceutical Administration Bureau of Macau for Nefecon® for the Treatment of Primary IgA Nephropathy

Everest Medicines Limited Announces Approval of XERAVA® in Taiwan for the Treatment of Complicated Intra-Abdominal Infections in Adult Patients

New major risk - Revenue and earnings growth

First half 2023 earnings released: CN¥1.40 loss per share (vs CN¥2.26 loss in 1H 2022)

Everest Medicines Announces New Drug Application Acceptance by the Pharmaceutical Administration Bureau of Macao for Nefecon(R) for the Treatment of Primary IgA Nephropathy

Everest Medicines Limited to Report First Half, 2023 Results on Aug 24, 2023

Everest Medicines Announces Completion of Patient Enrollment in Nefecon®? China Open Label Extension Study

Everest Medicines Announces Commercial Launch and First Prescription for XERAVA in China

Everest Medicines Appoints Mike Berry as Chief Technology Officer

Everest Medicines Limited, Annual General Meeting, Jun 29, 2023

Everest Medicines Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Etrasimod in Asia

No longer forecast to breakeven

Everest Medicines Announces South Korea Grants Fast Track Review Designation to Nefecon for the Treatment of Primary Iga Nephropathy

Everest Medicines Limited Announces Board Changes

Everest Medicines Announces Top-line Data from Phase I Study of EVER206 on Healthy Subjects in China

Everest Medicines Aims to Initiate Clinical Trials and File an Emergency Use Authorization Application in 2023 in China for Its Lead mRNA Candidate

Everest Medicines Announces China NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA Nephropathy

Everest Medicines Announces New mRNA Rabies Vaccine Program and Achievement of Preclinical Proof-of-Concept Milestone

Everest Medicines Announces Major Regulatory Updates in Taiwan and South Korea for Nefecon for the Treatment of Primary IgA Nephropathy

Less than half of directors are independent

Everest Medicines Announces New Drug Application Acceptance by China NMPA for Nefecon for the Treatment of Primary IgA Nephropathy

Everest Medicines Announces Approval of XERAVA in Hong Kong for the Treatment of Complicated Intra-Abdominal Infections

Forecast to breakeven in 2022

Everest Medicines Receives Approval of Investigational New Drug Application from China NMPA for EVER001

Everest Medicines Appoints Rogers Yongqing Luo as an Executive Director

Everest Medicines Limited Announces Resignation of Kerry Blanchard as A Member of the Board of Directors

Everest Medicines Limited to Report First Half, 2022 Results on Aug 24, 2022

Everest Medicines Announces Regulatory Update and Strategic Partnership for Xerava™ in Taiwan

Everest Medicines Announces Approval of Trodelvy in China for Second-Line Metastatic Triple-Negative Breast Cancer

Less than half of directors are independent

Everest Medicines Announces that Topline Results from Chinese Subpopulation Consistent With Global Phase 3 NefIgArd Study Part A Analysis

Everest Medicines Submits New Drug Application in Hong Kong for Sacituzumab Govitecan

Forecast to breakeven in 2024

Everest Medicines Limited, Annual General Meeting, Jun 30, 2022

Everest Medicines Limited Appoints Leah Liu as Joint Company Secretary

Everest Medicines Announces First Drug Approval of Trodelvy® in Singapore for Second-Line Metastatic Triple-Negative Breast Cancer

Everest Medicines Limited Announces Resignation of Ms. Yin Yin as Joint Company Secretary

Everest Medicines Will Participate in Clinical Trial with Gilead and Msd to Evaluate Trodelvy® in Combination with Keytruda® (Pembrolizumab) in First-Line Metastatic Non-Small Cell Lung Cancer

Everest Medicines Limited Announces Taiwan FDA Has Accepts New Drug Application for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer

Everest Medicines and Providence Therapeutics announces that PTX-COVID19-B, a mRNA Vaccine for COVID-19, has received approval for inclusion in WHO Solidarity Trial Vaccines (STV) Program

Everest Medicines Limited Announces Acceptance of New Drug Application for Sacituzumab Govitecan

Everest Medicines Limited Receives Approval for Investigational New Drug Application for SPR206 from National Medical Products Administration

Everest Medicines Announces First Person Dosed in Global Phase 3 Registration Trial of Sacituzumab Govitecan-Hziy in China for Metastatic Urothelial Cancer